Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon beta-1a in MS

摘要

Objective: To describe detailed MRI results from 2 head-to-head phase III trials, Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis Study I (CARE-MS I; NCT00530348) and Study II (CARE-MS II; NCT00548405), of alemtuzumab vs subcutaneous interferon beta-1a (SC IFN-beta-1a) in patients with active relapsing-remitting multiple sclerosis (RRMS).